This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
by Zacks Equity Research
Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
by Zacks Equity Research
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
by Zacks Equity Research
Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
by Zacks Equity Research
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
by Kinjel Shah
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.
The Zacks Analyst Blog Highlights Meta Platforms, Sanofi, CME and The Cato
by Zacks Equity Research
Meta Platforms, Sanofi, CME and The Cato are part of the Zacks top Analyst Blog.
Top Stock Reports for Meta, Sanofi & CME
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Meta Platforms, Inc. (META), Sanofi (SNY) and CME Group Inc. (CME), as well a micro-cap stock The Cato Corporation (CATO).
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
by Zacks Equity Research
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
by Zacks Equity Research
AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
by Zacks Equity Research
Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
by Zacks Equity Research
Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
by Zacks Equity Research
Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
by Zacks Equity Research
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
by Kinjel Shah
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
by Kinjel Shah
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
by Zacks Equity Research
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
by Zacks Equity Research
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.